| | COVID-19 clinical operations
ICON has adopted numerous measures to protect the welfare of patients, to protect the safety of our employees and to ensure the continuity of your research programmes during COVID-19. Learn more about how to keep your trial on track in this evolving environment.
|
Today's Rundown After sneak peak at early data, Operation Warp Speed head Slaoui 'confident' in COVID-19 vaccine by year's end States face looming crisis over Medicaid growth, which could trigger changes for providers and payers Sanofi Chairman Weinberg steps in after CEO says U.S. set to get first COVID-19 vaccines AMA issues guidance to physicians on using COVID-19 antibody tests Healthcare roundup: Fitbit plans to make ventilators; CDC issues alert on rare COVID-linked illness Biopharma roundup: Slaoui touts unnamed vaccine candidate; U.S. to stockpile promising COVID-19 shots Gilead may struggle to expand remdesivir's market to moderately ill COVID-19 patients: analyst Why Papa, Humana think it's crucial to 'make noise' about the impacts of loneliness amid COVID-19 FDA issues blanket COVID-19 authorization for IV infusion pumps Univercells inks deal to produce prefabricated vaccine facilities for potential COVID-19 shot Sutter Health suffered a $168M operating loss last month as COVID-19 upended finances What pandemic? With ADC's $233M listing, biotech IPOs keep on rolling Featured Story | | | President Donald Trump officially unveiled the "Operation Warp Speed" program and its leaders on Friday. The group aims to develop a COVID-19 vaccine by the end of the year, and its newly appointed head—GSK veteran and former Moderna board member Moncef Slaoui—said Friday he's "confident" the team can deliver. |
|
|---|
|
Top Stories Friday, May 15, 2020 States could face a major budget crisis due to the growth of Medicaid enrollment as unemployment skyrockets, which could have a big impact for providers and payers. Friday, May 15, 2020 Sanofi CEO Paul Hudson set off a firestorm this week by saying the U.S. would get priority for its COVID-19 vaccine thanks to early government funding for R&D. But now the company's chairman Serge Weinberg has intervened, stating unequivocally that countries will be "served at the same time." Friday, May 15, 2020 As new serology tests for COVID-19 rapidly come to the market, the American Medical Association is cautioning physicians about using these tests to make healthcare decisions for individual patients. The AMA issued guidance this week to help physicians understand the potential uses and limitations of serological testing, also called antibody testing. Friday, May 15, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Friday, May 15, 2020 The newly appointed head of the Trump administration's COVID-19 vaccine accelerator, project "Warp Speed," said data from an unnamed vaccine gave him hope that a shot could be ready to ship by the end of 2020. Moncef Slaoui, the former GSK vet, is a board member at Moderna, which is developing an mRNA shot. Friday, May 15, 2020 Gilead aims to develop easy-to-administer versions of its COVID-19 drug remdesivir, including one that could be inhaled. That could help expand the use of the drug in moderately ill patients. But proving remdesivir works in those patients will be a major hurdle, JPMorgan warned. Friday, May 15, 2020 The coronavirus pandemic has forced population health programs targeting loneliness to adapt to a new normal of social distancing. Friday, May 15, 2020 The FDA has issued another umbrella-style Emergency Use Authorization, covering infusion pumps, devices and accessories that are in high demand for treating patients with COVID-19. Friday, May 15, 2020 Manufacturing capacity has become a serious sticking point for drugmakers on the hunt for a COVID-19 vaccine as more industry insiders cast doubt on the supply chain's strength. But Belgian manufacturing specialist Univercells believes prefabricated vaccine facilities could help production scale up quickly. Friday, May 15, 2020 Sutter Health suffered a massive operating loss of $168 million in April as the COVID-19 pandemic has upended the system's finances. Friday, May 15, 2020 After pulling the plug on its first IPO attempt, ADC Therapeutics tried its luck during a pandemic. That gamble has paid off—the cancer drug developer reeled in $233 million in its Wall Street debut, outraising its original goal by more than $80 million. The proceeds will push the company’s lead programs through pivotal phase 2 studies. |
